Nakamoto Inc. (NAKA): Nasdaq/NYSE listing notice — Kindly MD receives Nasdaq deficiency notice for bid price below $1.00

Nakamoto Inc.

Closing bid price below $1.00 for 30 consecutive business days violates Nasdaq Global Market Rule 5450(a)(1).
Company has 180 calendar days, until June 8, 2026, to regain compliance by closing at $1.00+ for 10 consecutive business days.
Options to cure include reverse stock split or transfer to Nasdaq Capital Market with $5,000 application fee.
Failure to regain compliance could lead to delisting; company intends to actively monitor and consider remedies.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Nakamoto Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

December 10, 2025, Kindly MD, Inc., a Utah corporation (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. The notice has no present impact on the listing of the Company’s securities, and the Company’s common stock continues to t

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Nakamoto Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-027527

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.